NLRP3 and type 2 diabetes mellitus: Subsequently, these mice were treated with arglabin, which evidenced the inhibition of NLRP3 and its downstream cytokines, and thus the plasma levels of inflammatory cytokines decreased as well as the insulin resistance of the tissues, while T2DM improved.